DepoMed completes purchase of Nycunta (tapentadol) US rights for the treatment of pain from Janssen Pharmaceuticals

Depomed, Inc. announced that it has closed the acquisition of the U.S. rights to the Nucynta franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion. The Nucynta franchise includes: Nucynta ER (tapentadol) extended release tablets indicated for the management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN), severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta (tapentadol), an immediate release version of tapentadol, for management of moderate to severe acute pain in adults; and Nucynta (tapentadol) oral solution, an approved oral form of tapentadol that has not been launched. Nucynta is now the flagship asset in Depomed's growing portfolio of pain and neurology specialty pharmaceuticals.